After the approval of the General Controller of Medicines in India, the locally manufactured Corona virus vaccine in the country, Bharat Biotechnology Pharmaceuticals India once again knocked on the doors of the Medicines Control Unit to obtain permission to conduct clinical trials of an intranasal vaccine against the viral disease, and there are advantages in the Indian nasal vaccine for Corona virus It gives you a higher immunization against infection, according to thehealthsite.
As the name implies, a nasal vaccine is given through the nose, this is a non-invasive and painless way to administer the vaccine because it does not require a needle, this type of vaccine stimulates immunity through the inner surface of the nose, which is where the airborne microbes are exposed.
Single dose nasal vaccine
Clinical trials for “BBV154”, the new vaccine against intranasal adenoviruses for corona virus, will be conducted in different sites, the vaccine will be a single dose, according to the company, the intranasal vaccine stimulates a broad immune response at the site of infection, in the nasal mucosa, which is necessary to prevent infection And the transmission of the Corona virus.
Corona nasal vaccine–
–
–
A non-surgical alternative
The nasal vaccine differs from the two recently approved intramuscular vaccines, in that they are non-invasive, are needle-free, do not require trained healthcare workers, eliminate the risks associated with needles, are suitable for children and adults, and have a scalable manufacturing.
More effective than intramuscular vaccinations
The vaccine showed preventive effectiveness in mice and hamsters, and mice and hamsters vaccinated with a single dose gave superior protection against the challenge of the Corona virus, “more than one or two muscle immunizations from the same vaccine and dose.”
Corona nasal vaccine–
–
–
–
It creates an immune response in the nose
Bharat Biotech said in a statement that intranasal immunization for the Coronavirus can create an immune response in the nose, which is the entry point for the virus, and thus protect against disease, infection and transmission.
Approved vaccines are intramuscular vaccines
On January 3, the two intramuscular vaccines Coffeeshield and Coffaxine, from Oxford, AstraZeneca manufactured by the Serum Institute in India, were approved for use in emergency situations. They are both a two-dose vaccine, while the full effectiveness of Coffaxine has not yet been determined. Green light by DCGI, citing “Public Interest”.
Corona nasal vaccine –
–
– .
